Exai Bio

Private

Palo Alto, CaliforniaHealthcare & Life Scienceshttps://www.exai.bio

Last Round

Grant

Sep 1, 2024

Est. Valuation

$130.6M

Total Funding Raised

$139.38M

Momentum Score

25 /100

Company Overview

Exai Bio is a biotechnology company that specializes in a liquid biopsy platform for precise cancer diagnosis and personalized treatment guidance through the analysis of cell-free RNA profiles using advanced AI and machine learning.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Government Contracts

AI Layer

Application

Keywords

oncRNA-based liquid biopsy platformearly cancer detection blood testgenerative AI for cancer diagnosticstumor-naive minimal residual disease (MRD) detectionorphan non-coding RNA (oncRNA) biomarkerscancer treatment response monitoringRNA sequencing for cancer detectionnon-invasive cancer screeningliquid biopsy for therapy selectioncancer diagnostic platformbiomarker discovery services for biopharmaliquid biopsy for clinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exai Bio Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Exai Bio Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Sep 1, 2024
Series A Extension	Oct 10, 2022
Series A	Dec 9, 2021

View all Funding Rounds

Exai Bio Investors

Notable investors and investment history

Investor	Rounds
S32	Series A, Series A Extension
National Cancer Institute	Grant
Blue Cross Blue Shield Association	Series A
Moore Strategic Ventures	Series A Extension
Two Sigma Ventures	Series A, Series A Extension
Casdin Capital	Series A, Series A Extension

View all Investors

Exai Bio Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Exai Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Exai Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California

Employee Range23

Year Founded2018

Last FundingSep 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.